Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development...
December 04, 2025 22:05 ET | Source: Symbotic Inc.

Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock

WILMINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, today announced the pricing of its previously...
December 04, 2025 22:03 ET | Source: Protara Therapeutics

Protara Announces Pricing of $75 Million Public Offering

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...
December 04, 2025 21:45 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients...
December 04, 2025 19:56 ET | Source: CEA Industries Inc.

CEA Industries (Nasdaq: BNC) Responds to YZi Labs, Re-Affirms Commitment to BNB DAT Strategy, and Welcomes Shareholder Engagement

Shareholders do not need to take any action at this time Louisville, CO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq: BNC) (“BNC” or the “Company”), which manages the world’s...
December 04, 2025 19:00 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company...
December 04, 2025 19:00 ET | Source: FormFactor, Inc.

FormFactor Announces Participation in 14th Annual NYC Summit

LIVERMORE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) today announced that it will be joining 14 other companies in collectively hosting the 14th Annual NYC Summit...
December 04, 2025 17:59 ET | Source: authID Inc.

authID Selected to Biometrically Secure Identities for Online Educational Services at Correctional Facilities

Fastest-growing educational technology leader replaces homegrown solution with authID to enable authentication, protect privacy, and prevent fraud for distance learning in complex environments ...
December 04, 2025 17:37 ET | Source: Jefferson Capital

Jefferson Capital Completes Acquisition of Credit Card Portfolio

MINNEAPOLIS, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (NASDAQ: JCAP) (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off, insolvency and active...
December 04, 2025 17:20 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...